 |
NetWellness provides the highest quality health information and education services created and evaluated by faculty of our partner universities.
Friday, February 10, 2012
|
|
|
NetWellness provides the highest quality health information and education services created and evaluated by faculty of our partner universities.
Friday, February 10, 2012
|
| Home | HealthTopics | Health Centers | Reference Library | Research |
 Join us on Facebook
|
Share on Facebook | Tweet |
|
Myasthenia Gravis |
Myasthenia Gravis and Kidney Cancer04/01/2002 |
Dr. Kaminski; My husband was diagnosed with kidney cancer six months ago and underwent a complete removal of the kidney. He is NED at this time. Since then he has been in a clinical trial to try to extend his disease free time. In the trial the white blood cells are removed and treated with IL-2 and re-infused into the pt. Two weeks ago Ron, my husband was diagnosed with Myasthenia Gravis. Do you think the clinical trial could have caused the MG to appear at this time? Also, do you think the trial should be continued? The doctors at the trial feel that the two are unrelated, but I would like your oppinion. Thank you so much. We feel we have worked so hard to conqure the cancer that we may have caused the MG. Any comment?
Interleukin-2 (IL-2) is a medication that influences activities of the immune system and the naturally produced substance has been shown to be involved the pathogenesis of myasthenia gravis in animals with experimentally induced myasthenia gravis and in human myasthenia gravis. In patients who may be susceptible to the development of myasthenia gravis, treatment with IL-2 could be a factor in the development of MG. Below is a paper that describes a patient treated with IL-2 and interferon who developed myasthenia gravis. Please share my response with your physicians. Consideration needs to be given to the risks of continued treatment versus risk of worsening MG. It is important to appreciate that this complication is unlikely to apply to other patients and that risk of MG with IL-2 is likely to be very low.Rohde D, Sliwka U, Schweizer K, Jakse G. Oculo-bulbar myasthenia gravis induced by cytokine treatment of a patient with metastasized renal cell carcinoma. Eur J Clin Pharmacol 1996; 50:471-3.
|
Henry J Kaminski, MD Formerly, Professor of Neurology Department of Neurology School of Medicine Case Western Reserve University |
|
|
|
Please note: only your personal physician or other health professional you consult can best advise you on matters of your health based on your medical history, your family medical history, your medication history, and how information from any of these databases may apply to you. Neither University of Cincinnati (NetWellness) nor any party involved in creating, producing or delivering this web site shall be liable for any damages arising out of access to or use of this web site, or any errors or omissions in the content thereof. (More) 
|